SI3233850T1 - Hidroksi vsebujoč FXR (NR1H4) modulirajoče spojine - Google Patents
Hidroksi vsebujoč FXR (NR1H4) modulirajoče spojineInfo
- Publication number
- SI3233850T1 SI3233850T1 SI201530742T SI201530742T SI3233850T1 SI 3233850 T1 SI3233850 T1 SI 3233850T1 SI 201530742 T SI201530742 T SI 201530742T SI 201530742 T SI201530742 T SI 201530742T SI 3233850 T1 SI3233850 T1 SI 3233850T1
- Authority
- SI
- Slovenia
- Prior art keywords
- nr1h4
- modulating compounds
- hydroxy containing
- fxr
- containing fxr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14004259.9A EP3034501A1 (en) | 2014-12-17 | 2014-12-17 | Hydroxy containing FXR (NR1H4) modulating compounds |
EP15816665.2A EP3233850B1 (en) | 2014-12-17 | 2015-12-14 | Hydroxy containing fxr (nr1h4) modulating compounds |
PCT/EP2015/002511 WO2016096115A1 (en) | 2014-12-17 | 2015-12-14 | Hydroxy containing fxr (nr1h4) modulating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3233850T1 true SI3233850T1 (sl) | 2019-06-28 |
Family
ID=52338776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201530742T SI3233850T1 (sl) | 2014-12-17 | 2015-12-14 | Hidroksi vsebujoč FXR (NR1H4) modulirajoče spojine |
Country Status (22)
Country | Link |
---|---|
US (1) | US9751874B2 (sl) |
EP (2) | EP3034501A1 (sl) |
JP (1) | JP6452820B2 (sl) |
KR (1) | KR101998007B1 (sl) |
CN (1) | CN108064223B (sl) |
AU (1) | AU2015365944B2 (sl) |
BR (1) | BR102015031718A2 (sl) |
CA (1) | CA2971240C (sl) |
EA (1) | EA201791017A1 (sl) |
ES (1) | ES2730757T3 (sl) |
HK (1) | HK1251552A1 (sl) |
IL (1) | IL252677A0 (sl) |
MX (1) | MX2017007981A (sl) |
NZ (1) | NZ732246A (sl) |
PL (1) | PL3233850T3 (sl) |
PT (1) | PT3233850T (sl) |
SG (1) | SG11201704618RA (sl) |
SI (1) | SI3233850T1 (sl) |
TR (1) | TR201909093T4 (sl) |
TW (1) | TWI697483B (sl) |
UY (1) | UY36445A (sl) |
WO (1) | WO2016096115A1 (sl) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
SI3277286T1 (sl) | 2015-03-31 | 2021-09-30 | Enanta Pharmaceuticals, Inc. | Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo |
WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
PL3730487T3 (pl) | 2016-06-13 | 2022-08-16 | Gilead Sciences, Inc. | Pochodne azetydyny jako modulatory fxr (nr1h4) |
AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
WO2018059314A1 (zh) * | 2016-09-28 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
WO2018133858A1 (en) * | 2017-01-22 | 2018-07-26 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ, インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
SG11201908235RA (en) | 2017-04-12 | 2019-10-30 | Il Dong Pharmaceutical Co Ltd | An isoxazole derivatives as nuclear receptor agonists and used thereof |
WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
EP3650449B1 (en) * | 2017-07-06 | 2023-08-23 | Xuanzhu Biopharmaceutical Co., Ltd. | Fxr receptor agonist |
CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
WO2019055808A1 (en) | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS |
EA202091101A1 (ru) * | 2017-11-01 | 2020-08-06 | Бристол-Маерс Сквибб Компани | Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора |
WO2019089664A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
CN111630051B (zh) * | 2017-11-01 | 2023-12-26 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃螺环化合物 |
JP7212693B2 (ja) | 2017-11-01 | 2023-01-25 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしての架橋二環化合物 |
ES2944657T3 (es) | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
WO2019118571A1 (en) * | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US11339153B2 (en) | 2018-08-08 | 2022-05-24 | Inorbit Therapeutics Ab | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same |
AU2020209564B2 (en) | 2019-01-15 | 2022-12-01 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | Fxrアゴニストの固体形態 |
KR20220003558A (ko) * | 2019-04-19 | 2022-01-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Fxr 소분자 작용제 및 이의 제조 방법과 용도 |
CN111825667B (zh) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
WO2020231917A1 (en) * | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CN114173784B (zh) | 2019-07-18 | 2023-12-01 | 埃尼奥制药公司 | 降低干扰素的副作用的方法 |
JP2022541503A (ja) | 2019-07-23 | 2022-09-26 | ノバルティス アーゲー | Fxrアゴニストを使用した肝疾患の組み合わせ処置 |
JP2022541307A (ja) | 2019-07-23 | 2022-09-22 | ノバルティス アーゲー | Fxrアゴニストを含む処置 |
CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
US20220347190A1 (en) | 2019-09-19 | 2022-11-03 | Novartis Ag | Treatment comprising fxr agonists |
JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Fxrアゴニストの使用を含む処置 |
TW202135811A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
EP4090327A1 (en) | 2020-01-15 | 2022-11-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of fxr agonists for treating an infection by hepatitis d virus |
WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN114195786B (zh) * | 2020-09-18 | 2023-08-22 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114195776B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114195777B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114315830A (zh) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
CA3204800A1 (en) | 2021-01-14 | 2022-07-21 | Raphael Darteil | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
CN117865941B (zh) * | 2024-03-13 | 2024-06-28 | 上海方予健康医药科技有限公司 | 取代哌啶化合物及其制备方法和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
AU2003225903A1 (en) | 2002-03-21 | 2003-10-08 | Curagen Corporation | Methods of using farnesoid x receptor (fxr) agonists |
JP2006515838A (ja) | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
WO2004087076A2 (en) | 2003-03-31 | 2004-10-14 | The Rockefeller University | Methods for inhibiting adipogenesis and for treating type 2 diabetes |
JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
US7863302B2 (en) | 2006-02-03 | 2011-01-04 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
JP5119241B2 (ja) | 2006-05-24 | 2013-01-16 | イーライ リリー アンド カンパニー | Fxrアゴニスト |
CL2007001451A1 (es) | 2006-05-24 | 2008-01-11 | Eli Lilly And Company Soc Organizada Bajo Las Leyes Del Estado De Indiana | Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas. |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
BRPI0812521A2 (pt) | 2007-06-13 | 2015-06-23 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto |
KR20100044810A (ko) | 2007-07-02 | 2010-04-30 | 글락소스미스클라인 엘엘씨 | 파네소이드 x 수용체 효능제 |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
AU2008339572B2 (en) * | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
US20140039007A1 (en) | 2010-12-20 | 2014-02-06 | David C. Tully | Compositions and methods for modulating farnesoid x receptors |
WO2012087520A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
-
2014
- 2014-12-17 EP EP14004259.9A patent/EP3034501A1/en not_active Withdrawn
-
2015
- 2015-12-14 ES ES15816665T patent/ES2730757T3/es active Active
- 2015-12-14 MX MX2017007981A patent/MX2017007981A/es active IP Right Grant
- 2015-12-14 AU AU2015365944A patent/AU2015365944B2/en active Active
- 2015-12-14 CN CN201580069167.6A patent/CN108064223B/zh active Active
- 2015-12-14 WO PCT/EP2015/002511 patent/WO2016096115A1/en active Application Filing
- 2015-12-14 PL PL15816665T patent/PL3233850T3/pl unknown
- 2015-12-14 TR TR2019/09093T patent/TR201909093T4/tr unknown
- 2015-12-14 JP JP2017530023A patent/JP6452820B2/ja active Active
- 2015-12-14 SG SG11201704618RA patent/SG11201704618RA/en unknown
- 2015-12-14 PT PT15816665T patent/PT3233850T/pt unknown
- 2015-12-14 CA CA2971240A patent/CA2971240C/en active Active
- 2015-12-14 EA EA201791017A patent/EA201791017A1/ru unknown
- 2015-12-14 NZ NZ732246A patent/NZ732246A/en unknown
- 2015-12-14 EP EP15816665.2A patent/EP3233850B1/en active Active
- 2015-12-14 KR KR1020177019299A patent/KR101998007B1/ko active IP Right Grant
- 2015-12-14 SI SI201530742T patent/SI3233850T1/sl unknown
- 2015-12-16 UY UY0001036445A patent/UY36445A/es not_active Application Discontinuation
- 2015-12-16 US US14/971,875 patent/US9751874B2/en active Active
- 2015-12-17 BR BR102015031718A patent/BR102015031718A2/pt not_active IP Right Cessation
- 2015-12-17 TW TW104142586A patent/TWI697483B/zh active
-
2017
- 2017-06-05 IL IL252677A patent/IL252677A0/en unknown
-
2018
- 2018-08-23 HK HK18110840.1A patent/HK1251552A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TWI697483B (zh) | 2020-07-01 |
PL3233850T3 (pl) | 2019-09-30 |
BR102015031718A2 (pt) | 2016-07-05 |
MX2017007981A (es) | 2017-09-29 |
JP6452820B2 (ja) | 2019-01-16 |
KR101998007B1 (ko) | 2019-07-08 |
CN108064223A (zh) | 2018-05-22 |
CA2971240A1 (en) | 2016-06-23 |
WO2016096115A1 (en) | 2016-06-23 |
CN108064223B (zh) | 2021-06-01 |
SG11201704618RA (en) | 2017-07-28 |
UY36445A (es) | 2016-07-29 |
IL252677A0 (en) | 2017-08-31 |
AU2015365944B2 (en) | 2019-01-17 |
EA201791017A1 (ru) | 2018-01-31 |
KR20170095955A (ko) | 2017-08-23 |
US9751874B2 (en) | 2017-09-05 |
JP2018500304A (ja) | 2018-01-11 |
AU2015365944A1 (en) | 2017-06-15 |
TR201909093T4 (tr) | 2019-07-22 |
HK1251552A1 (zh) | 2019-02-01 |
CA2971240C (en) | 2019-07-02 |
EP3233850A1 (en) | 2017-10-25 |
PT3233850T (pt) | 2019-06-19 |
ES2730757T3 (es) | 2019-11-12 |
EP3034501A1 (en) | 2016-06-22 |
NZ732246A (en) | 2018-11-30 |
US20160176861A1 (en) | 2016-06-23 |
EP3233850B1 (en) | 2019-04-03 |
TW201638073A (zh) | 2016-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251552A1 (zh) | 含羥基的fxr(nr1h4)調節化合物 | |
HK1245786B (zh) | 新的fxr(nr1h4)調節化合物 | |
IL263495A (en) | Modulating compounds (fxr (nr1h4 | |
IL263493B (en) | Modulating compounds (fxr (nr1h4 | |
GB201409044D0 (en) | New compounds | |
HRP20181530T1 (hr) | Novi sulfonilaminobenzamidni spojevi | |
GB201404498D0 (en) | New compounds | |
GB201416444D0 (en) | New compounds | |
GB201403437D0 (en) | Easy click box | |
HK1226059A1 (zh) | 新的fxr(nr1h4)調節化合物 | |
IL247610A0 (en) | chemical compounds | |
GB201418676D0 (en) | Compounds for use | |
GB201409792D0 (en) | Compounds for use | |
GB201401792D0 (en) | Beta-lactam compounds | |
GB201421211D0 (en) | Chemical compounds | |
GB201417344D0 (en) | New compounds | |
GB201417346D0 (en) | New compounds | |
GB201416430D0 (en) | New compounds | |
GB201403122D0 (en) | New chemical compounds | |
GB201402647D0 (en) | New compounds |